Immunic Cash Flow To Debt Ratio vs Ev To Free Cash Flow Analysis
IMUX Stock | USD 1.38 0.04 2.99% |
Immunic financial indicator trend analysis is infinitely more than just investigating Immunic recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunic is a good investment. Please check the relationship between Immunic Cash Flow To Debt Ratio and its Ev To Free Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.
Cash Flow To Debt Ratio vs Ev To Free Cash Flow
Cash Flow To Debt Ratio vs Ev To Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunic Cash Flow To Debt Ratio account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Immunic's Cash Flow To Debt Ratio and Ev To Free Cash Flow is -0.23. Overlapping area represents the amount of variation of Cash Flow To Debt Ratio that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Immunic, assuming nothing else is changed. The correlation between historical values of Immunic's Cash Flow To Debt Ratio and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flow To Debt Ratio of Immunic are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Cash Flow To Debt Ratio i.e., Immunic's Cash Flow To Debt Ratio and Ev To Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.23 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cash Flow To Debt Ratio
Ev To Free Cash Flow
A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 66K | 1.0M | 3.1M | 3.2M | Interest Income | 66K | 1.0M | 3.1M | 3.2M |
Immunic fundamental ratios Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
Other Current Liab | 343K | 4.7M | 585K | 8.2M | 18.9M | 19.9M | |
Total Current Liabilities | 7.1M | 8.4M | 11.4M | 13.1M | 24.7M | 26.0M | |
Total Stockholder Equity | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
Property Plant And Equipment Net | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
Net Debt | (28.8M) | (126.8M) | (86.3M) | (105.2M) | (45.3M) | (47.6M) | |
Retained Earnings | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (410.9M) | (390.3M) | |
Accounts Payable | 2.4M | 3.7M | 3.7M | 4.3M | 5.1M | 3.9M | |
Cash | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
Non Current Assets Total | 33.7M | 34.1M | 34.1M | 1.9M | 1.8M | 1.7M | |
Cash And Short Term Investments | 29.4M | 127.5M | 86.9M | 116.4M | 46.7M | 66.0M | |
Common Stock Shares Outstanding | 7.7M | 15.7M | 23.7M | 31.8M | 44.3M | 46.5M | |
Liabilities And Stockholders Equity | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
Non Current Liabilities Total | 520K | 679K | 584K | 992K | 639.0K | 607.0K | |
Other Current Assets | 2.9M | 1.2M | 18.1M | 9.5M | 5.2M | 4.1M | |
Other Stockholder Equity | 53.7M | 266.8M | 324.2M | 427.9M | 436.1M | 245.3M | |
Total Liab | 7.6M | 9.1M | 12.0M | 14.1M | 25.4M | 26.6M | |
Property Plant And Equipment Gross | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
Total Current Assets | 32.2M | 133.7M | 105.0M | 125.9M | 52.5M | 70.8M | |
Accumulated Other Comprehensive Income | (1.4M) | (4.1M) | (252K) | 3.0M | 3.8M | 3.9M | |
Non Currrent Assets Other | 108K | 37K | 42K | 43K | 38.7K | 36.8K | |
Net Tangible Assets | 25.4M | 125.8M | 94.1M | 113.7M | 130.7M | 80.6M | |
Retained Earnings Total Equity | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (285.6M) | (299.8M) | |
Capital Surpluse | 119.6M | 266.8M | 324.2M | 427.9M | 492.1M | 326.3M | |
Non Current Liabilities Other | 520K | 679K | 584K | 992K | 1.1M | 1.2M | |
Property Plant Equipment | 80K | 203K | 1.1M | 294K | 264.6K | 251.4K | |
Other Assets | 37K | 42K | 943K | 43K | 49.5K | 47.0K | |
Net Receivables | 408K | 1.6M | 2.2M | 2.7M | 703K | 1.3M | |
Net Invested Capital | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
Net Working Capital | 25.2M | 125.3M | 93.6M | 112.8M | 27.8M | 26.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Transaction History View history of all your transactions and understand their impact on performance | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.